StockData

Curis vs TScan Therapeutics

CRIS and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRIS and TCRX compare

TScan Therapeutics is the larger company, worth 9.0 times as much as Curis ($10.2M against $1.1M).

TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −62.2% for Curis).

Curis keeps more of each dollar of sales as profit, with a net margin of −490% compared with −1655% at TScan Therapeutics.

Curis scores higher on the StockData Score (7 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRISTCRX
Size and price
Market cap$1.1M$10.2M
Share price$0.542$0.151
Change, 1 year−98.0%−86.3%
Change, 5 years−100.0%−98.3%
Beta (5Y)−0.102.15
Employees24142
StockData Score
Total score7 (better)4
Valuation score33
Growth score00
Performance score00
Health score4 (better)1
Dividend score00
Valuation
P/S0.3× (better)1.4×
P/B0.2×0.1× (better)
FCF yield–−1157%
Fair value$6.75$1.36
Margin of safety92.0% (better)88.9%
Growth
Revenue growth (TTM)−62.2%2.2% (better)
Revenue growth, 5Y average−2.7%56.9% (better)
Profitability
Operating margin−203% (better)−1695%
Net margin−490% (better)−1655%
FCF margin–−1666%
Return on equity–−95.8%
Financial health
Debt / equity0.000.47 (better)
Interest coverage–−43.2×
Current ratio0.493.37 (better)
Altman Z-score−96.17−6.31 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield−2171%–
Shareholder yield−2171%0.00% (better)
Ownership
Held by institutions32.1%53.5%
Held by insiders20.4%32.8%
Insider net buying, 12 months$5.5K$146K (better)
Short interest, % of float61.8%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.